Sorrento Therapeutics Inc (SRNE)

[dia76ca]

Here are some of the top portfolio items we might see updated at this weeks 2 presentations. Updates on STIX / ABI / SP102 / DROPS could be highlights IMO!

COVITRACE™ (diagnostic) Diagnostic Test
FDA Emergency Use Authorization (EUA) Application Expected

COVISTIX™ (diagnostic) Antigen Test
FDA Emergency Use Authorization (EUA) Application Submitted

COVITRACK™ – Platinum (diagnostic) Next Generation Antibody Test
In final manufacturing and clinical testing
*
COVIGUARD™ (treatment) Neutralizing Antibody (IV) in Inpatients
*
COVI-AMG™ (treatment) Neutralizing Antibody (IV) in Outpatients
*
COVIDROPS™ (treatment) Neutralizing Antibody (Intranasal) in Outpatients
*
COVISHIELD™ (treatment) Neutralizing Abs (IV) in Inpatients
*
COVIDTRAP™ (treatment) ACE2 Receptor Decoy (IV) in Inpatients
*
ABIVERTINIB (treatment) Severe or Critical COVID-19 in ICU Patients
*
SALICYN – 30 (treatment) Anti-viral
*
COVI-MSC (treatment) ARDS due to COVID-19 in ICU Pts
*
Immunotherapy
CD38 CAR-T Multiple Myeloma
*
CD38 DAR-T Multiple Myeloma
*
CD38 ADC Amyloidosis
*
Seprehvir™ Solid Tumors
*
Seprehvec™ Solid Tumors
*
ABIVERTINIB NSCLC
*
ADNIC Solid and Liquid Tumors
*
Pain

SP-102 back and sciatic pain
*
RTX (resiniferatoxin)
Epidural route Intractable Pain in Advanced Cancer
*Orphan designation

RTX (resiniferatoxin)
Intra-articular route Moderate to Severe OA
*
Lymphatic Delivery
Sofusa® anti-TNF Autoimmune
*
Sofusa® anti-PD-1 CTCL
*